Human phase‐I metabolism of three synthetic cannabinoids bearing a cumyl moiety and a cyclobutyl methyl or norbornyl methyl tail: Cumyl‐CBMEGACLONE, Cumyl‐NBMEGACLONE, and Cumyl‐NBMINACA

Synthetic cannabinoid receptor agonists (SCRAs) continue to show high prevalence on the new psychoactive substances drug market. Around 2019–2020, new SCRAs bearing a cumyl moiety emerged: Cumyl‐CBMEGACLONE and Cumyl‐NBMEGACLONE, carrying a cyclobutyl methyl (CBM) and a norbornyl methyl moiety (NBM) attached to the γ‐carbolinone core. These were followed by Cumyl‐NBMINACA, the indazole carboxamide analog of Cumyl‐NBMEGACLONE. The study aimed at evaluating the human phase‐I metabolism of these compounds and at identifying suitable urinary markers to prove their consumption. After enzymatic hydrolysis, 14 authentic urine samples (eight for Cumyl‐CBMEGACLONE, four for Cumyl‐NBMEGACLONE, and two for Cumyl‐NBMINACA) were analyzed by liquid chromatography–quadrupole time‐of‐flight mass spectrometry. Results were compared with in vitro metabolites generated by pooled human liver microsomes incubation. Fifteen human phase‐I metabolites were identified for Cumyl‐CBMEGACLONE, nine for Cumyl‐NBMEGACLONE, and thirteen for Cumyl‐NBMINACA. The main in vivo metabolites were built by monohydroxylation, dihydroxylation, or trihydroxylation. The following urinary biomarkers are suggested for detecting the consumption of the investigated SCRAs: products of monohydroxylation at the CBM and at the core for Cumyl‐CBMEGACLONE; two products of monohydroxylation at the norbonyl methyl tail for Cumyl‐NBMEGACLONE; and metabolites built by dihydroxylation at the NBM substructure and by an additional hydroxylation at the cumyl moiety for Cumyl‐NBMINACA.